Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Candid Care
San Diego, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Two bispecific T-cell engager antibodies (BCMAxCD3 and CD20xCD3) completed Phase 1 dose escalation in oncology and entered Phase 2 trials in multiple autoimmune indications in 2025. Both drugs showed strong efficacy signals in over 130 oncology patients, are now being tested in autoimmune diseases with early clinical data pending
- Therapeutic areas
- ImmunologyNeurologyNephrologyRheumatology
- Modalities
- Bispecific monoclonal antibodyAntibody
- Industry
- Biotech
02
Partnerships
Licensing from EpimAb Biotherapeutics (for BCMAxCD3 candidate)Licensing from Genor Biopharma (for CD20xCD3 candidate)
Beyond the preview
Go deeper on Candid Care.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Candid Care.